QCG
SYRE icon

Quadrant Capital Group’s Spyre Therapeutics SYRE Stock Holding History

Quadrant Capital Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-146
Closed -$7.37K – 2432
2026
Q1 		$7.37K Buy
+146
New +$5.5K ﹤0.01% 2272
2022
Q1 		– Sell
-45
Closed -$5K – 2687
2021
Q4 		$5K Hold
45
– – ﹤0.01% 1902
2021
Q3 		$9K Hold
45
– – ﹤0.01% 1660
2021
Q2 		$8K Hold
45
– – ﹤0.01% 1685
2021
Q1 		$9K Hold
45
– – ﹤0.01% 1565
2020
Q4 		$9K Hold
45
– – ﹤0.01% 1448
2020
Q3 		$8K Hold
45
– – ﹤0.01% 1340
2020
Q2 		$11K Buy
+45
New +$8.57K ﹤0.01% 1297

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Quadrant Capital Group's SYRE Position: Q2 2026 in Review

Quadrant Capital Group sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 146 shares — an estimated $7.37K sold.

Quadrant Capital Group first reported a position in SYRE in Q2 2020 and held it in 8 quarters. The position peaked at $11K in Q2 2020. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Quadrant Capital Group reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 146 Spyre Therapeutics shares in Q2 2026, an estimated $7.37K.
  • Quadrant Capital Group first reported a position in Spyre Therapeutics in Q2 2020 and held it in 8 quarters.
  • Quadrant Capital Group's Spyre Therapeutics position peaked at $11K in Q2 2020.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.